HM3A Vivactis

HM3A Vivactis is a #consultancy agency specialized in #market #access for #pharmaceutical and #medical devices.
Based in Brussels, we network throughout Europe.

[HM3A Vivactis @Hm3aV]

Betalen wij dubbel voor onze geneesmiddelen? https://t.co/W7VJPcSau9 via @medischcontact

[HM3A Vivactis @Hm3aV]

Reimagining commercialisation with AI https://t.co/TwtuyDhBVp

[HM3A Vivactis @Hm3aV]

read about patient rights and healtheconomics in Belgium https://t.co/iI8qbLVcHe

[HM3A Vivactis @Hm3aV]

‘Landmark’ day for Akcea as NICE recommends Tegsedi in rare inherited hATTR https://t.co/SagFB9rylC

[HM3A Vivactis @Hm3aV]

I'm going to "MedTech Accelerator® 2019 : Discover Medtech innovations developed in your...". See you there? https://t.co/y20iyrYm4n via @Eventbrite

[HM3A Vivactis @Hm3aV]

Catalyst shares dive amid speculation about ‘off-label’ rare disease rival https://t.co/Bi0RprvgyL via @pharmaphorum

[HM3A Vivactis @Hm3aV]

UK government revamps efforts to hasten access to new drugs https://t.co/BWltPI3rGg via @pharmaphorum

[HM3A Vivactis @Hm3aV]

De vrouw die fake news over vaccins bestrijdt https://t.co/sIexRWBZkU via @HLN_BE

[HM3A Vivactis @Hm3aV]

Drug middlemen point finger at pharma in US pricing debate https://t.co/IE5PL0ct1Z

[Vivactis Group @VivactisGroup]

HM3A Vivactis new website is live !
Want information regarding #MarketAccess, #Public and #Governmental Affairs as well as #Regulatory Affairs and #RiskManagement services ?
Click here ➡️ https://t.co/n5NeR4t9CU

[HM3A Vivactis @Hm3aV]

Hello Twitter! #myfirstTweet